With at least 18 ANDA sponsors submitting applications for a generic version of Novartis’ blockbuster heart failure therapy Entresto (sacubitril/valsartan), the Swiss originator has petitioned the US Food and Drug Administration to refrain from approving any generics before a key date in February 2024, in part because of a landmark new indication Novartis won for Entresto at the beginning of this year.
In a 29-page citizen petition submitted to the US regulator, Novartis points to its FDA approval in February 2021 of...




